Sexton Riley LLP represented Janssen Biotech, Inc. in a license agreement with LegoChem Biosciences, Inc. for LCB84, a clinical stage Trop2-directed ADC.
top of page
© 2024 by Sexton Riley Hearn LLP. All rights reserved. Attorney advertising.
bottom of page
Comments